EFFECTS OF 4-HYDROXYANDROST-4-ENE-3,17-DIONE AND ITS METABOLITES ON 5-ALPHA-REDUCTASE ACTIVITY AND THE ANDROGEN RECEPTOR

被引:10
作者
DAVIES, JH
SHEARER, RJ
ROWLANDS, MG
POON, GK
HOUGHTON, J
JARMAN, M
DOWSETT, M
机构
[1] INST CANC RES,CANC RES CAMPAIGN LAB,DRUG DEV SECT,COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND
[2] ROYAL MARSDEN HOSP,DEPT ACAD BIOCHEM,LONDON SW3 6JJ,ENGLAND
来源
JOURNAL OF ENZYME INHIBITION | 1992年 / 6卷 / 02期
基金
英国医学研究理事会;
关键词
4-HYDROXYANDROST-4-ENE-3,17-DIONE; 5-ALPHA-REDUCTASE; ANDROGEN RECEPTOR;
D O I
10.3109/14756369209040745
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The steroidal aromatase inhibitor, 4-hydroxyandrost-4-ene-3,17-dione (40HA) and its metabolites, 4-hydroxytestosterone (4OHT), 3beta, 17-dihydroxy-5alpha-androstan-4-one (metabolite A) and 3alpha,17-dihydroxy-5beta-androstan-4-one (metabolite B) were evaluated as inhibitors of the human prostatic 5alpha-reductase enzyme and for binding to the rat prostatic androgen receptor. 4OHA and 4OHT were weak inhibitors of 5alpha-reductase with IC50 values of 15-29 muM. Metabolites A and B had no significant inhibitory activity. 40HA and metabolites A and B bound weakly to the androgen receptor. The binding affinities (RBA) relative to mibolerone (RBA = 100) were 0.085, 0.485 and 0.016, respectively. However, 4OHT (RBA = 75) was a more potent binder than the endogenous androgen 5alpha-dihydrotestosterone (RBA = 66). The ability of these metabolites, in particular 4OHT, to bind to the androgen receptor may explain the in vivo androgenic activity of 4OHA.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 30 条
  • [1] DELETION OF STEROID 5-ALPHA-REDUCTASE 2-GENE IN MALE PSEUDOHERMAPHRODITISM
    ANDERSSON, S
    BERMAN, DM
    JENKINS, EP
    RUSSELL, DW
    [J]. NATURE, 1991, 354 (6349) : 159 - 161
  • [2] METABOLISM OF THE AROMATASE INHIBITOR 4-HYDROXY-4-ANDROSTENE-3,17-DIONE BY MALE RHESUS-MONKEYS
    BRODIE, AMH
    ROMANOFF, LP
    WILLIAMS, KIH
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1981, 14 (08) : 693 - 696
  • [3] BRODIE AMH, 1989, CANCER RES, V49, P6551
  • [4] 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER
    COOMBES, RC
    GOSS, P
    DOWSETT, M
    GAZET, JC
    BRODIE, A
    [J]. LANCET, 1984, 2 (8414) : 1237 - 1239
  • [5] DAVIES JH, 1991, IN PRESS BR J CANCER
  • [6] DOWSETT M, 1989, CANCER RES, V49, P1306
  • [7] THE EFFECTS OF AMINOGLUTETHIMIDE AND HYDROCORTISONE, ALONE AND COMBINED, ON ANDROGEN LEVELS IN POST-ORCHIECTOMY PROSTATIC-CANCER PATIENTS
    DOWSETT, M
    SHEARER, RJ
    PONDER, BAJ
    MALONE, P
    JEFFCOATE, SL
    [J]. BRITISH JOURNAL OF CANCER, 1988, 57 (02) : 190 - 192
  • [8] DRAGO JR, 1984, CANCER-AM CANCER SOC, V53, P1447, DOI 10.1002/1097-0142(19840401)53:7<1447::AID-CNCR2820530703>3.0.CO
  • [9] 2-G
  • [10] METABOLISM OF 4-HYDROXYANDROST-4-ENE-3,17-DIONE BY RAT HEPATOCYTES
    FOSTER, AB
    JARMAN, M
    MANN, J
    PARR, IB
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1986, 24 (02) : 607 - 617